PanCD44 Immunohistochemical Evaluation in Prostatectomies from Patients with Adenocarcinoma
المؤلفون المشاركون
da Cunha, Maria do Perpétuo Socorro Saldanha
Hirth, Carlos Gustavo
Santos, Adriele Machado dos
Cerqueira, João Batista Gadelha de
Jamacaru, Francisco Vagnaldo Fechine
Dornelas, Conceição Aparecida
المصدر
العدد
المجلد 2018، العدد 2018 (31 ديسمبر/كانون الأول 2018)، ص ص. 1-7، 7ص.
الناشر
Hindawi Publishing Corporation
تاريخ النشر
2018-02-26
دولة النشر
مصر
عدد الصفحات
7
التخصصات الرئيسية
الملخص EN
Introduction.
CD44 has been proposed as a prognostic marker and a stem cell marker but studies in patients with prostate cancer have yielded inconsistent results.
Patients and Methods.
Patients submitted to radical prostatectomy between 2008 and 2013 at a university hospital were followed with biannual serum PSA tests to determine the biochemical recurrence (BR).
Archived paraffin blocks with neoplastic and nonneoplastic tissue were evaluated immunohistochemically for a panCD44 and MYC.
Results.
Sixty-nine patients completed follow-up and were included.
CD44 positivity was observed in inflammatory cells (42%), nonneoplastic epithelium (39.7%), and neoplastic tissue (12.3%).
In nonneoplastic tissues staining was observed in basal and luminal cells with the morphology of terminally differentiated cells.
In neoplastic tissues, CD44 negativity was correlated with higher Gleason scores (Rho = −0.204; p=0.042) and higher preoperative serum PSA levels when evaluated continuously (p=0.029).
CD44 expression was not associated with tumor stage (p=0.668), surgical margin status (p=0.471), or BR (p=0.346), nor was there any association between CD44 and MYC expression in neoplastic tissue (p=1.0).
Conclusion.
In the bulk of cells, the minority of cancer stem cells would not be detected by immunohistochemistry using panCD44.
As a prognostic marker, its expression was weakly correlated with Gleason score and preoperative PSA level, but not with surgical margin status, tumor stage, or BR.
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
Hirth, Carlos Gustavo& Santos, Adriele Machado dos& Cerqueira, João Batista Gadelha de& Jamacaru, Francisco Vagnaldo Fechine& da Cunha, Maria do Perpétuo Socorro Saldanha& Dornelas, Conceição Aparecida. 2018. PanCD44 Immunohistochemical Evaluation in Prostatectomies from Patients with Adenocarcinoma. BioMed Research International،Vol. 2018, no. 2018, pp.1-7.
https://search.emarefa.net/detail/BIM-1124862
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
Hirth, Carlos Gustavo…[et al.]. PanCD44 Immunohistochemical Evaluation in Prostatectomies from Patients with Adenocarcinoma. BioMed Research International No. 2018 (2018), pp.1-7.
https://search.emarefa.net/detail/BIM-1124862
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
Hirth, Carlos Gustavo& Santos, Adriele Machado dos& Cerqueira, João Batista Gadelha de& Jamacaru, Francisco Vagnaldo Fechine& da Cunha, Maria do Perpétuo Socorro Saldanha& Dornelas, Conceição Aparecida. PanCD44 Immunohistochemical Evaluation in Prostatectomies from Patients with Adenocarcinoma. BioMed Research International. 2018. Vol. 2018, no. 2018, pp.1-7.
https://search.emarefa.net/detail/BIM-1124862
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references
رقم السجل
BIM-1124862
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر